Goodwin Procter LLP advised CRISPR Therapeutics on the deal. CRISPR Therapeutics (NASDAQ: CRSP) announced its collaboration agreement with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) to develop, manufacture, and...
CRISPR Therapeutics’ Collaboration Agreement with Vertex Pharmaceuticals
CRISPR Therapeutics’ Collaboration Agreement with Vertex Pharmaceuticals
Goodwin Procter LLP advised CRISPR Therapeutics on the deal. CRISPR Therapeutics (NASDAQ: CRSP) announced its collaboration agreement with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) to develop, manufacture, and...
Cerevel Therapeutics’ $125 Million Non-dilutive Financing Transaction for Tavapadon
Goodwin Procter LLP advised Cerevel Therapeutics on the deal. Ropes & Gray represented Bain Capital, while Wyrick Robbins Yates & Ponton LLP acted as legal counsel...
Better Therapeutics’ $187 Million Merger Agreement with Mountain Crest Acquisition Corp II
Goodwin Procter LLP advised Better Therapeutics, Inc. on the deal. Better Therapeutics, Inc. announced its definitive merger agreement with Mountain Crest Acquisition Corp II (Nasdaq: MCAD;), a...
Insightful Science’s Acquisition of Dotmatics
Goodwin Procter LLP advised Dotmatics, while Willkie Farr & Gallagher LLP advised Insightful Science on the deal. Insightful Science, a leading software provider serving the global...
BridgeBio Pharma’s $2.45 Billion Collaboration and Licensing Agreement with Helsinn Group
Goodwin Procter LLP advised BridgeBio Pharma, Inc. on the deal. BridgeBio Pharma, Inc. (Nasdaq: BBIO) and its affiliate QED Therapeutics, Inc. announced a global collaboration and licensing...
Rapid7’s $525 Notes Offering
Goodwin Procter LLP advised the initial purchasers on the deal. Rapid7, Inc. (Nasdaq: RPD) announced the Rule 144A offering of $525 million principal amount of its 0.25% Convertible...
Everbridge, Inc.’s $375 Million Notes Offering
Goodwin Procter LLP advised the initial purchasers on the deal. Everbridge, Inc. (“Everbridge”) issued an aggregate of $375 million principal amount of its 0% Convertible Senior Notes...
Cutera’s $138.25 Million Notes Offering
Goodwin Procter LLP advised the initial purchasers on the deal. Cutera, Inc. (the “Company”) entered into a purchase agreement (the “Purchase Agreement”) with Stifel, Nicolaus & Company,...
ElevateBio’s $525 Million Series C Financing
Goodwin Procter LLP advised ElevateBio on the deal. ElevateBio, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, announced it...
MannKind Corporation’s $230 Million Notes Offering
Goodwin Procter LLP advised the initial purchasers on the deal. MannKind Corporation (the “Company”) completed its previously announced private offering (the “Offering”) of $200.0 million aggregate...